RANI Rani Therapeutics Holdings, Inc. stock chart & analysis
Conviction 45HealthcareScan · Wed, Nov 4, 2026Rani Therapeutics Holdings, Inc. (RANI) closed at $0.5756 (+3.56%) on Nov 4, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 33, RS Rating 6, -78.1% from its 52-week high, -57.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why RANI moved
From the StockSetups movers recaps that covered RANI, newest first. A recap states what was known that day.
- Close+29.8%
No specific catalyst headline or press release is on file for today's move. The most recent SEC filing is a June 30 8-K classified as a management event.
Top Stock Movers Today — July 22, 2026: Why KSCP, SMCX, RANI & NIPG Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
RANI technical analysis
Trend
RANI is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 23.2% below the 50-day ($0.7491) and 37.5% below the 200-day ($0.9206). ADX(14) at 40 points to a strong, established trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 33, in the bearish half of its range. The MACD histogram is negative. Its RS Rating of 6 puts its weighted 12-month performance ahead of about 6% of the US market.
Volume and volatility
Volume on the latest session ran 0.3× its 20-day average. It trades about $330,708 a day on average. ATR(14) is $0.0425, 7.4% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.38) shows distribution.
Key levels
The chart pattern's support is $0.6522 and its resistance $0.8645. The 52-week range is $0.5500 to $2.63; price is 78.1% below the high and 4.7% above the low. The VWAP anchored at the 52-week high is $1.26, above price.
Performance
RANI returned -6.5% (1 week), -30.6% (1 month), -26.3% (3 months), -40.1% (6 months), -73.2% (1 year), -57.4% (year to date).
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Pharmaceutical Preparations · Listed 2021 · 69 employees
Insider activity
SEC Form 4 transactions in RANI
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Javadi Alireza Chief Technical Officer · Stock Option (Right to Buy) · 2026-06-03 | Grant | 805.5K | $0 | 2026-06-03 | 2026-06-05 |
Imran Talat Chief Executive Officer · Stock Option (Right to Buy) · 2026-06-03 | Grant | 3.8M | $0 | 2026-06-03 | 2026-06-05 |
McKinley Kate Chief Business Officer · Stock Option (Right to Buy) · 2026-06-03 | Grant | 805.5K | $0 | 2026-06-03 | 2026-06-05 |
Bassan Abraham Director · Director Stock Option (Right to Buy) · 2026-05-28 | Grant | 123.6K | $0 | 2026-05-28 | 2026-06-01 |
Bailey Vasudev Jaiprakash Director · Director Stock Option (Right to Buy) · 2026-05-28 | Grant | 123.6K | $0 | 2026-05-28 | 2026-06-01 |
Rometty Lisa Ann Director · Director Stock Option (Right to Buy) · 2026-05-28 | Grant | 123.6K | $0 | 2026-05-28 | 2026-06-01 |
BUTEL JEAN LUC Director · Director Stock Option (Right to Buy) · 2026-05-28 | Grant | 123.6K | $0 | 2026-05-28 | 2026-06-01 |
Ausiello Dennis A Director · Director Stock Option (Right to Buy) · 2026-05-28 | Grant | 123.6K | $0 | 2026-05-28 | 2026-06-01 |
IMRAN MIR A Director · Director Stock Option (Right to Buy) · 2026-05-28 | Grant | 123.6K | $0 | 2026-05-28 | 2026-06-01 |
SEC filings
EDGAR filings in RANI · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.